Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on May 27, 2008
JNCI Journal of the National Cancer Institute 2008 100(11):764-766; doi:10.1093/jnci/djn187
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/11/764    most recent
djn187v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tuma, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tuma, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

NEWS

Drugs To Prevent Colon Cancer Show Promise, But Hurdles Remain for Chemoprevention

Rabiya Tuma

The first 150 words of the full text of this article appear below.

A low-dose combination of sulindac and difluoromethylornithine (DFMO) reduced the risk of recurrent colorectal adenomas by 70% and high-risk adenomas by 92% compared with placebo in a randomized controlled trial, researchers reported in April at the annual meeting of the American Association for Cancer Research (AACR). Also, 5-year follow-up data from the Adenoma Prevention with Celecoxib (APC) trial showed that individuals who took celecoxib during the trial continued to be at lower risk of developing adenomas 2 years after they stopped taking the drug, compared with participants who took a placebo.

These results could fundamentally change chemoprevention, experts agree. The magnitude of the benefit in the sulindac–DFMO trial was larger than expected for any type of chemoprevention. (As designed, the trial would have been deemed a success if the combination had reduced the risk by 50%.) And the trial is the first to show that a combination of chemoprevention drugs . . . [Full Text of this Article]

Chemoprevention With Sulindac and DFMO

Five-Year APC Results

Celecoxib Safety

Overcoming Hurdles for Prevention


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Prevention ResearchHome page
A. Boquoi, T. Chen, and G. H. Enders
Chemoprevention of Mouse Intestinal Tumorigenesis by the Cyclin-Dependent Kinase Inhibitor SNS-032
Cancer Prevention Research, September 1, 2009; 2(9): 800 - 806.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
S. Paul, A. M. Rimando, H. J. Lee, Y. Ji, B. S. Reddy, and N. Suh
Anti-inflammatory Action of Pterostilbene Is Mediated through the p38 Mitogen-Activated Protein Kinase Pathway in Colon Cancer Cells
Cancer Prevention Research, July 1, 2009; 2(7): 650 - 657.
[Abstract] [Full Text] [PDF]